Posts tagged “Quintiles”
The N.C. Biotech Center notes recent wins of three Triangle life science firms whose start included support from the Biotech Center
Clinical trial services are Quintiles' bread and butter but the CRO industry's largest company sees other growth opportunities. Read more about Quintiles strategy.
While pharmas, payers and providers have historically operated in silos, collaborations will be key for the future of health care, according to a new Quintiles report.
Biotech IPOs represented 13 of the 21 venture-capital companies that went public in the second quarter. Get more more details of an analysis of second quarter IPOs.
Several high-tech and life science firms based in North Carolina or who have a large presence here crack the "Best Multinationals" to work for list in Europe. But several of them also drop somewhat from the 2012 list.
The RX for a healthier bottom line at the world's largest life science services firm includes better employee health. A new award in the U.K. honors Quintiles for its commitment to a healthy workplace. WRALTechWire's exclusive interview with the associate director of Quintiles Employee Health Management provides the inside story.
Quintiles stock has consistently traded above its $43 per share IPO price. Read how analysts are rating the stock of the Durham CRO.
Quintiles uterine fibroids treatment research is being funded by the Patient-Centered Outcomes Research Institute, or PCORI, which researches health outcomes and comparative effectiveness of treatments.
Quintiles and the Duke Clinical Research Institute are very different providers of clinical trial services but pharma executives give both high marks. Learn what makes them stand out.
Another life science services firm in the Triangle, PRA International, may follow in the footsteps of a bigger rival - Quintiles - by offering stock in order to raise capital. Just two years ago, PRA was at the center of takeover rumors in the range of $1 billion.
Fresh off an IPO that produced $1 billion for investors and the company, Quintiles on Wednesday announced a drug development deal in which it will work with Germany-based Merck Serono. But this contract is much different from others in which Quintiles shared some of the financial risk for new drug development. WRALTechWire Insiders get the story beyond the press release.
Quintiles completes its IPO selling 27.2 million shares, including the overallotment sold by investors who took stakes in Quintiles when it was private. Read just how much they stand to gain from the additional sale.
Chairman and co-founder Dr. Dennis Gillings joins his company's executive management team for the ringing of the opening bell on the NYSE on Friday. Quintiles executed the biggest IPO in Triangle history on Thursday.
Dennis Gillings, who started Quintiles in a trailer more than 30 years ago, rings the opening bell on the New York Stock Exchange today to celebrate the giant's return to public markets. Stephen Wiehe, who led SciQuest through a similar private-to-public Odyssey, recalls the "humbling" ringing bell honor.
Following Quintiles initial public stock offering, Chief Operating Officer John Ratliff gave WRAL Tech Wire an interview from the New York Stock Exchange. Read what he has to say about the now public company.